Anti-CCR7 antibody drug conjugates

US11634497B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Steven Bender · Oceanside, US
• Tracy Charlton · San Diego, US
• Anna Galkin · Encinitas, US
• Bernhard Hubert Geierstanger · Solana Beach, US
• Scott Glaser · San Diego, US
• Shailaja Kasibhatla · San Diego, US
• Mark Knuth · El Cajon, US
• Sabine ROTTMANN · San Diego, US
• Sarah Rue · San Diego, US
• Glen Spraggon · San Diego, US
• Tetsuo Uno · San Diego, US

Key dates

• Filing date: Feb 1, 2018
• Grant date: Apr 25, 2023
• Expiry date: Apr 20, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.